旋风加速器无限安卓

There is a pressing unmet need for more effective treatments of Pulmonary Arterial Hypertension. A progressive disease caused by cell proliferation in lung blood vessels, PAH (high blood pressure in lung arteries) can adversely affect the heart.
More

旋风加速器无限安卓

We have developed a new class of inhalable drugs to decrease cell proliferation, instead of merely “relaxing” pulmonary arteries as today’s vasodilators do. Our hope after clinical trials is to prove greater efficacy with fewer side effects.
More

旋风加速器无限安卓

In solving the unique problems of our own pulmonary drug research, Pulmokine has developed patented inhalation systems and preclinical efficacy solutions that we are making available to the pulmonary drug development community.
酸酸乳节点网站

旋风加速器无限安卓

Pulmokine is interested in strategic partnerships with leading pharmaceutical corporations, R&D firms, licensors and/or investors to take our breakthrough technologies into the next phases of clinical development.